Von ATH zu ATH - der Neue Markt is back.

Bloß jetzt mit Substanzwerten: Biotech mit ner fetten Pipeline und fetten Gewinnen im letzten Jahr, so dass der Cash sich verdoppelt hat. Haben inzwischen ne eigene Produktionsstätte.

Dagegen sind Morphosys, GPC und Co nur Krempel. Bei ner entsprechenden Performance müsste Morphosys jetzt bei 600 stehen und GPC bei 90. Kriegen die aber nie (oder in 10 Jahren) auf die Reihe.

Noch mal - einer der besten Bio-techs worldwide:

www.bavarian-nordic.com

Aber ich predige schon seit ewigen Zeiten - und keiner hat ne Meinung dazu.

Schätze mal, dass das nächste Ding bei Mologen abgehen wird. Muss ja auch keiner ernstnehmen.  

Ich kann mich auch dunkel erinnern, das du (?) die schon mal empfohlen hast. Aber den Vergleich mit dem Neuen Markt würde ich nicht ziehen - der wird BAVA nicht gerecht.

Ich schau sie mir in den nächsten Wochen mal an und kaufe dann vielleicht ein paar bei nem Rücksetzer auf knapp unter 40 EUR - Das könnte langfristig ne schöne Unterstützung werden.

Übrigens hat die Firma nen vorzüglichen Internetauftritt - danke!

Fussball- Grüße

Boxenbauer  

@Bb - den Chart mit den Peergroups find ich gut

 

 

 

um den Kurs von Januar 01 zu überbieten reichen 200 bei MOR, da braucht es keine 600.... ;-)

Grüße
ecki  

apropo ATH...wie sieht es mit
ner Seite aus!? Hatten am Samstag drüber
gesprochen...  

- muss ich wohl verpennt haben. sach einfach mal.  

 

 

 

Heute ein bisschen angeschrammt - aber ansonsten?
http://biz.yahoo.com/rc/040310/health_smallpox_2.html
 

Natürlich hat wieder keiner nen Interesse an dem Wert.  

 

Dicom und fortunecity.

Obwohl ich von dem Zeug auch mehr habe als das tägliche Handeslvolumen beträgt.

Auf der Watchlist steht noch Mologen - mal sehn.  

Heute die 55 geknackt.

Und dann gibts doch wirklich noch welche, die auf GPC, Morphosys oder son Zeug setzen. komisch.  

 

(zumindest die Haupt-Message)

Nordea starter dækning af Bavarian Nordic med Strong Buy

16. juni 2004 kl. 09:27 - Finans
Nordea Securities har onsdag morgen startet dækning af Bavarian Nordic-aktien med en stærk købsanbefaling (Strong Buy), fremgår det af en kommentar fra banken.
Banken peger på, at der er adskillige kortsigtede kurstriggere i aktien.
Aktien sluttede tirsdag i kurs 420. (© 2004 NetPosten)
 

...oder Däne einspringen...?
Thanx,
Nussriegel

nen dankbaren Wert hast du da vorgestellt, karlchen!
@ posting Nr. 3:
mal schaun, ob BAWA nicht eher auf 200 steht als GPC (hihihi)


AKTIER: APM steg kraftigt efter handelsstop - Bavarian efterspurgt
28. maj 2004 kl. 17:03 - Finans

Det danske aktiemarked oplevede en moderat positiv dag, hvor handelen først på eftermiddagen blev afbrudt i en time på grund af tekniske problemer, og hvor A.P. Møller-Mærsk efterfølgende oplevede en markant stigning.

Det toneangivende KFX-indeks lukkede 1,59 point (0,6 pct.) højere i 253,14.

Meget af stigningen i KFX skyldes en positiv stemning i A.P. Møller-Mærsk , der sluttede 4,8 pct. højere i 39.600 kr. Aktien følger de asiatiske shipping-aktier op - bl.a. er Evergreen steget knap 3 pct. i nat og i alt 8 pct. over de seneste tre dage.

Desuden har APM Terminals ifølge shippingavisen Lloyd's List underskrevet en to-årig aftale om at varetage den jordanske havn Aqaba Container Terminals, der er blevet en af hovedfærdselsårerne for varer til Irak.

Københavns Lufthavne er helt sikker på et come-back i det toneangivende KFX-indeks, når den nye indekssammensætning udvælges på tirsdag den 1. juni. Selskabet har med en omsætning på ca. 1,5 mia. kr. siden december endda overhalet Coloplast, der nu sidder på det yderste mandat i KFX-familien. Københavns Lufthavne endte 0,7 pct. lavere i 864 kr.

Bavarian Nordic er rykket tættere på en ordre fra USA på sin 3.-generations koppevaccine, og ifølge analytikere vurderede selskabet på torsdagens virksomhedsdag i Finansanalytikerforeningen, at der er 98 pct. chance for en ordre. Dog må en sådan ordre efterhånden være priset ind i kursen, der er steget ca. 85 pct. på 6 måneder. Aktien lukkede 3,1 pct. højere i 405 kr., en ny rekord.

Vestas' spanske vindmøllerival Gamesa fastholdt fredag forventningerne til helåret og meddelte samtidig på et pressemøde, at selskabet undersøger mulighederne for en ekspansion i Asien. Vestas endte 0,6 pct. højere i 81 kr.

Af Jean M. Dühring, jean@netposten.dk (© 2004 NetPosten)
 

Bavarian Nordic er rykket tættere på en ordre fra USA på sin 3.-generations koppevaccine, og ifølge analytikere vurderede selskabet på torsdagens virksomhedsdag i Finansanalytikerforeningen, at der er 98 pct. chance for en ordre. Dog må en sådan ordre efterhånden være priset ind i kursen, der er steget ca. 85 pct. på 6 måneder.
Aktien lukkede 3,1 pct. højere i 405 kr., en ny rekord.

Bavarian Nordic:Laut Gerücht soll Bavaria Nordic von USA eine Order für seine 3.Generation von Impfstoff erhalten und infolgedessen werteten die Analysten die Gesellschaft so ,dass eine 98% Chance besteht den Auftrag zu erhalten.Doch auch mit dem Auftrag wäre das im Kurs eingepreist,der in 6 Monaten bereits um 85% stieg.Die Aktie stieg 3,1% auf 405 KR, ein neuer Rekord.  

ich denke, das war genau der wichtige kern der message
bist du fit in dänisch oder hast du ein babelfish-tool, dass das kann?
und....was meinst du zu dem wert?
Thanx sagt
Nussriegel  

Aber keinen interessiert es - die gucken nur auf GPC oder so nen zeug.  

bin nicht reich genug, um Geld mit GPC zu verbrennen.
lassen wir die liebe BayN einfach laufen.
ist doch ne schöne Art, Kohle zu verdienen.
 

...für diejenigen, die es interessiert *g*

BAVARIAN NORDIC RES. DK10  
WKN: 917165 ISIN: DK0015998017 
http://www.bavarian-nordic.com

falls es die Tabelle unten zerrupft, findest ihr sie unter
http://www.danskaktieanalyse.dk/...l=briefing/vis_selskab.asp?ID=3444

 

KONCERNTAL DKK('000)19992000200120022003Nettoomsætning000121.077504.642Resultat af primær drift-65.853-79.129-93.480-26.650214.039Finansielle poster, netto8964.3152.5369363.589Resultat af ordinær drift-64.957-74.814-90.944-25.714217.628Ekstraordinære poster00000Skat001.143-95.83467.063Nettoresultat-64.957-74.814-92­.08770.120150.565Ordinært resultat efter skat-64.957-74.814-92.08770.120150.565Udbytte %0,000,000,000,000,00Aktiekapital27.05027.34233.55345.14545.145Eg­enkapital134.59162.32544.143196.439347.001Balance152.80083.69261.­874317.701429.169Antal medarbejdere5463727282Soliditet88,174,571,361,880,9EPS-24,0-27,7-­30,217,633,4BVPS49,822,813,243,576,9

Delårstal 20043 mdr.halvår9 mdr.Nettoomsætning109.20000Resultat af primær drift48.70000Resultat før skat52.90000Resultat efter skat og min.37.70000

 

und dann noch ein bissl was zum Unternehmen:

 

COPENHAGEN, Denmark, May 11 /PRNewswire/ --

- To The Copenhagen Stock Exchange

Bavarian Nordic announced today positive results in its global development programme of IMVAMUNE(TM) as a safe third-generation MVA smallpox vaccine. Results from the recently-completed Phase ll dose finding trial with IMVAMUNE(TM) in 165 healthy volunteers reconfirmed the strong safety and immunogenicity profile of the vaccine as reported from an earlier Phase I trial.
In this Phase ll trial, IMVAMUNE(TM) was found to have an excellent safety profile at all three dose levels tested. No serious adverse reactions were reported. Of the adverse reactions reported, the majority were mild-to-moderate injection site reactions.
More importantly these adverse events did not result in impairment of daily activities, indicating the superior tolerability of IMVAMUNE(TM) over traditional smallpox vaccines. In similar studies with traditional smallpox vaccines such as DryVax (R) , more than one-third of the subjects were sufficiently ill to miss work, school or recreational activities.
All volunteers who received the highest dose level of IMVAMUNE(TM) exhibited an excellent and rapid immune response, demonstrated by 94.2% sero-conversion after one vaccination and 100% after two vaccinations. Even more noteworthy was the immune response seen in the two low-dose groups. All subjects in these groups sero-converted after having received the full vaccination course. Further follow-up studies to evaluate the persistence of the immune response are planned.
Commenting on this latest development, Peter Wulff, President and CEO of Bavarian Nordic said, "The results of this Phase II study are very exciting and further justify the acceleration of our global clinical development of IMVAMUNE(TM). These results, along with our announcement last week to begin for the first time ever a Phase l trial with IMVAMUNE in atopic dermatitis, represent significant progress in our path to globally register IMVAMUNE(TM) as a safe third-generation smallpox vaccine for the general population, including the immune compromised."
Asger Aamund, Chairman of the Board
About Bavarian Nordic:
Founded in 1994, Bavarian Nordic A/S is a leading biopharmaceutical company in the field of innovative vaccines to prevent and treat infectious diseases. With operations in Denmark and Germany, Bavarian Nordic employs over 100 people and is listed on the Copenhagen Stock Exchange under the trading symbol BAVA.
Bavarian Nordic''s proprietary core technology MVA-BN (R) , is one of the world''s safest, multivalent vaccine vectors and ideally suited for use against various infectious diseases such as smallpox, HIV, Japanese Encephalitis and Dengue Fever. Several MVA-BN (R) -based HIV and smallpox vaccines are in clinical Phase I and Phase II trials.
With respect to smallpox vaccines, Bavarian Nordic has supply and development contracts with the governments of Germany, the U.S.A., and other countries. One of the company''s development agreements includes a three-year contract (awarded in February 2003) with the U.S. Department of Health and Human Services to develop MVA-BN (R) as a safe third-generation smallpox vaccine.
Bavarian Nordic is one of the few companies in the world able to supply the growing demand for smallpox vaccines, particularly safe smallpox vaccines. With the acquisition of a manufacturing facility in Denmark able to produce up to 120 million doses per year and a separate pilot facility in Berlin, Germany, Bavarian Nordic has established its own production capabilities and ensured the supply of its current and future vaccines.
Bavarian Nordic''s partners include Epimmune of the U.S.A., Gerolymatos of Greece, Impfstoffwerk Dessau-Tornau (IDT) of Germany, and Vaccine Solutions of Australia.
For more information please visit www.bavarian-nordic.com

Bavarian Nordic A/S

© PR Newswire

__________________________________________________
 

COPENHAGEN, Denmark, May 5 /PRNewswire/ --

Bavarian Nordic A/S announced today that the U.S. Food and Drug Administration (FDA) has approved the company''s Investigational New Drug Application (IND) for its third-generation smallpox vaccine candidate to enter further clinical trials. Bavarian Nordic will immediately start a Phase l study with IMVAMUNE(TM), its safe third-generation smallpox vaccine, in 60 subjects including persons suffering from atopic dermatitis. This study will be conducted in Europe with the final report expected in 2005.
Persons with atopic dermatitis, more commonly known as eczema, are at risk in suffering potentially severe side effects from first and second generation smallpox vaccines. These persons as well as others in the known high-risk groups (immune compromised, pregnant, young, elderly, etc.) hould not be given these vaccines.
Peter Wulff, President and CEO said, "With this latest IND, we will initiate, for the first time ever, a trial in a significant population of people that cannot safely receive the current smallpox vaccine. While the next phase in the US government''s MVA smallpox vaccine development programme (RFP-2 to be awarded in summer 2004) will require clinical trials in high-risk populations, we already
have data on some risk groups from our recombinant vaccine development programme. Our decision to start this trial in atopic dermatitis now - rather than wait until RFP-2 is awarded - is based on our goal of registering IMVAMUNE(TM) as a safe smallpox vaccine for the general population as soon as possible."
In addition and as reported last week, another Phase l trial with IMVAMUNE(TM) in 90 subjects is underway in the USA. This study will compare IMVAMUNE(TM) to the licensed smallpox vaccine DryVax (R) and will investigate whether the immune response against IMVAMUNE(TM) protects against a subsequent challenge with DryVax (R) . This trial is sponsored by the U.S. National Institute of Health and is expected to be completed in 2005.
The company will also start a Phase l trial in the third quarter of 2004, which will investigate IMVAMUNE (TM) in people with HIV. While Bavarian Nordic has already conducted trials in this risk group in Europe, it will be conducted again in the USA as a requirement of RFP-1. First results of this trial are expected in 2005. Asger Aamund, Chairman of the Board

 

vergessen wir mal so Langweilerwerte wie GPC etc.